Newport Beach, CA, June 15, 2020 – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today that Joanna Kemp, BSN, RN, has joined the team as Director of Clinical Programs. In this role, Kemp will collaborate with clinicians, industry, patients, and other experts to develop and maintain best care practices for Duchenne. She will work closely with Duchenne experts and the CureDuchenne team to create educational content for the Duchenne community and present to diverse audiences at CureDuchenne events and medical conferences.
“We are very excited to have Joanna join our team – she has exactly the skill set we need to continue serving the Duchenne community with programs designed to improve the lives of everyone affected by this devastating disease,” said Debra Miller, Founder and CEO, CureDuchenne.
Kemp is a licensed registered nurse, holding a Bachelor of Science in Nursing from the University of Pennsylvania. She has spent over a decade working in clinical trials, both as a research nurse and in leadership roles, and previously coordinated a pediatric specialty program at Yale University. Most recently, Joanna worked as the Director of the Cancer Clinical Trials Office at Beth Israel Deaconess Medical Center in Boston, Massachusetts, where she oversaw a staff of over 70 clinical trial professionals and managed a $1.8mil annual operating budget.
“I am looking forward to applying my 15 years of professional experience in clinical care and clinical trials to CureDuchenne and facilitate meaningful changes to those living with Duchenne muscular dystrophy by bridging the current standards with the many therapies in development. Mostly though, I am excited to become a member of the impressive Duchenne community who represents the gold standard of family and clinician-based disease advocacy,” said Kemp.
CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 individuals living today. CureDuchenne is dedicated to finding and funding a cure for Duchenne by breaking the traditional charitable mold through an innovative venture philanthropy model that funds groundbreaking research, early diagnosis, and community education. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org.